BR112023000975A2 - Regime e formulação de baixa dose de um composto 5-metil-1,2,4-oxadiazol-3-ila - Google Patents
Regime e formulação de baixa dose de um composto 5-metil-1,2,4-oxadiazol-3-ilaInfo
- Publication number
- BR112023000975A2 BR112023000975A2 BR112023000975A BR112023000975A BR112023000975A2 BR 112023000975 A2 BR112023000975 A2 BR 112023000975A2 BR 112023000975 A BR112023000975 A BR 112023000975A BR 112023000975 A BR112023000975 A BR 112023000975A BR 112023000975 A2 BR112023000975 A2 BR 112023000975A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- oxadiazol
- formulation
- methyl
- low dose
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
REGIME E FORMULAÇÃO DE BAIXA DOSE DE UM COMPOSTO 5-METIL-1,2,4-OXADIAZOL-3-ILA. A presente invenção refere-se a um composto de Fórmula I: , ou um sal farmaceuticamente aceitável do mesmo, em que o composto de Fórmula I, ou sal farmaceuticamente aceitável do mesmo é administrado por via oral com uma dose total do composto de 0,1 mg/dia a 5 mg/dia, útil para o tratamento de uma doença neurodegenerativa, incluindo tauopatias neurodegenerativas, como a doença de Alzheimer, demência frontotemporal, síndrome corticobasilar e paralisia supranuclear progressiva.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063055362P | 2020-07-23 | 2020-07-23 | |
PCT/US2021/042877 WO2022020663A1 (en) | 2020-07-23 | 2021-07-23 | Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112023000975A2 true BR112023000975A2 (pt) | 2023-02-07 |
Family
ID=77338898
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112023000975A BR112023000975A2 (pt) | 2020-07-23 | 2021-07-23 | Regime e formulação de baixa dose de um composto 5-metil-1,2,4-oxadiazol-3-ila |
Country Status (18)
Country | Link |
---|---|
US (1) | US20230338349A1 (pt) |
EP (1) | EP4185291A1 (pt) |
JP (1) | JP2023535034A (pt) |
KR (1) | KR20230043905A (pt) |
CN (1) | CN116323604A (pt) |
AR (1) | AR123031A1 (pt) |
AU (1) | AU2021312894A1 (pt) |
BR (1) | BR112023000975A2 (pt) |
CA (1) | CA3186808A1 (pt) |
CL (1) | CL2023000194A1 (pt) |
CO (1) | CO2023000594A2 (pt) |
DO (1) | DOP2023000009A (pt) |
EC (1) | ECSP23005057A (pt) |
IL (1) | IL300023A (pt) |
MX (1) | MX2023000993A (pt) |
PE (1) | PE20231031A1 (pt) |
TW (1) | TW202220650A (pt) |
WO (1) | WO2022020663A1 (pt) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2023216231A1 (en) | 2022-02-03 | 2024-08-01 | Eli Lilly And Company | Regional tau imaging for diagnosing and treating alzheimer's disease |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI654978B (zh) | 2017-01-27 | 2019-04-01 | 美商美國禮來大藥廠 | 5-甲基-1,2,4-二唑-3-基化合物 |
JP2021530552A (ja) * | 2018-07-31 | 2021-11-11 | イーライ リリー アンド カンパニー | 併用療法 |
-
2021
- 2021-07-21 TW TW110126729A patent/TW202220650A/zh unknown
- 2021-07-21 AR ARP210102050A patent/AR123031A1/es unknown
- 2021-07-23 MX MX2023000993A patent/MX2023000993A/es unknown
- 2021-07-23 WO PCT/US2021/042877 patent/WO2022020663A1/en active Application Filing
- 2021-07-23 AU AU2021312894A patent/AU2021312894A1/en active Pending
- 2021-07-23 PE PE2023000107A patent/PE20231031A1/es unknown
- 2021-07-23 JP JP2023504346A patent/JP2023535034A/ja active Pending
- 2021-07-23 CN CN202180063288.5A patent/CN116323604A/zh active Pending
- 2021-07-23 KR KR1020237005839A patent/KR20230043905A/ko active Search and Examination
- 2021-07-23 CA CA3186808A patent/CA3186808A1/en active Pending
- 2021-07-23 BR BR112023000975A patent/BR112023000975A2/pt unknown
- 2021-07-23 US US18/005,245 patent/US20230338349A1/en active Pending
- 2021-07-23 IL IL300023A patent/IL300023A/en unknown
- 2021-07-23 EP EP21755253.8A patent/EP4185291A1/en active Pending
-
2023
- 2023-01-19 CL CL2023000194A patent/CL2023000194A1/es unknown
- 2023-01-19 CO CONC2023/0000594A patent/CO2023000594A2/es unknown
- 2023-01-20 DO DO2023000009A patent/DOP2023000009A/es unknown
- 2023-01-23 EC ECSENADI20235057A patent/ECSP23005057A/es unknown
Also Published As
Publication number | Publication date |
---|---|
CO2023000594A2 (es) | 2023-01-26 |
JP2023535034A (ja) | 2023-08-15 |
TW202220650A (zh) | 2022-06-01 |
PE20231031A1 (es) | 2023-07-10 |
KR20230043905A (ko) | 2023-03-31 |
CA3186808A1 (en) | 2022-01-27 |
ECSP23005057A (es) | 2023-02-28 |
EP4185291A1 (en) | 2023-05-31 |
US20230338349A1 (en) | 2023-10-26 |
IL300023A (en) | 2023-03-01 |
CL2023000194A1 (es) | 2023-07-21 |
MX2023000993A (es) | 2023-03-01 |
AU2021312894A1 (en) | 2023-02-23 |
CN116323604A (zh) | 2023-06-23 |
DOP2023000009A (es) | 2023-02-15 |
WO2022020663A1 (en) | 2022-01-27 |
AR123031A1 (es) | 2022-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2011057204A2 (en) | Lrrk2-mediated neuronal toxicity | |
GT200800256A (es) | Derivados de pirazolo [3,4-d]-pirimidina útiles para tratar trastornos respiratorios | |
BR112015016911A2 (pt) | tiadiazol, análogos dos mesmos e métodos de tratamento de condições relacionadas à deficiência de smn | |
NI201100100A (es) | Moduladores de aril metil benzoquinazolinona alostéricos positivos del receptor m1. | |
PE20160195A1 (es) | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington | |
EA201491606A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
BR112014027010A2 (pt) | uso de laquinimod de alta dose para tratamento de esclerose múltipla | |
BR112013000190A2 (pt) | formas de dosagem de retenção gástrica compreendendo um análogo de gaba e um opioide | |
BR112019002513A2 (pt) | uso e dosagem de agentes terapêuticos para endometriose | |
BR112022005595A2 (pt) | Composto, medicamento, métodos para inibir histona deacetilase 6 e para profilaxia ou tratamento de doença de alzheimer ou paralisia supranuclear progressiva em um mamífero, e, uso de composto | |
BR112023000975A2 (pt) | Regime e formulação de baixa dose de um composto 5-metil-1,2,4-oxadiazol-3-ila | |
BR112015014433A2 (pt) | compostos tricíclicos | |
JOP20190058A1 (ar) | مشتقات كرومان، أيزوكرومان وداي هيدرو أيزو بنزوفوران كمُعدلات تفارغية سالبة mGluR2، تركيبات، واستخدامها | |
BR112023025789A2 (pt) | Nitroxolina para uso no tratamento de neurofibroma cutâneo | |
BR112018068784A2 (pt) | método para o tratamento de leucemia | |
BR112012020060B8 (pt) | uso de n-((1-((4-hidroxitetrahidro-2h-piran-4-il)metil)piperidin-4-il)metil)-3-isopropil-2-oxo-2,3-dihidro-1h-benzo[d]imidazol-1-carboxamida para tratar doença de alzheimer e demência | |
BR112019024804A2 (pt) | compostos bicíclicos 5,6-fundidos e composições para o tratamento de doenças parasíticas | |
BR112014004339A2 (pt) | suspensão oral | |
BR0308045A (pt) | Aplicação de 3-fenil-5-alcóxi-1,3,4-oxdiazol-2-onas substituìdas para a preparação de medicamentos com efeito inibidor na lipase pancreática | |
BR112019005578A2 (pt) | compostos de indazol para uso em lesões no tendão e/ou ligamento | |
NO20090814L (no) | N-fenyl-prenylamin derivater for behandling av kognitive, neurodegenerative eller neurone sykdommer eller lidelser | |
BR112023025552A2 (pt) | Composições estabilizadas de apilimod e usos das mesmas | |
BRPI0606750A2 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, e,composição farmacêutica | |
NO20090812L (no) | Fenyl-prenyl-eter derivater for behandling av kognitive, neurodegenerative eller neurone sykdommer eller lidelser | |
BR112023017999A2 (pt) | Obicetrapibe para tratamento de demências |